First Trust NYSE Arca Biotechnology Index Fund (FBT)

135.76
Delayed Data
As of 4:10pm ET
 -0.67 / -0.49%
Today’s Change
98.65
Today|||52-Week Range
147.10
+8.98%
Year-to-Date

Investment Objective

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. It is non-diversified.

No recent news for First Trust NYSE Arca Biotechnology Index Fund.

Performance

1 month+2.43% 3 years+6.07%
3 months+10.64% 5 years+22.77%
1 year+33.94% Since inception+18.00%
Data through 02/22/2018

Quote Details

Previous close$136.43
Open day’s range135.60 – 138.09
Net asset value (NAV)136.31 (02/21/2018)
Daily volume39,041
Average volume (3 months)61,362
Data as of 4:10pm ET, 02/22/2018

Peer Comparisonvs. Health ETFs

 FBTCategory
Performance 5-yr return+22.77%+17.28%
Expense Gross exp ratio0.56%1.31%
Risk 5 year sharpe ratio1.001.11
Net assets$1.4B$3.2B
Average market cap$12.0B$9.5B
Average P/E--22.6
Dividend / Share--0.34%

Competitors

XLV Health Care Select Sector SPDR® Fund
RYH Guggenheim S&P 500® Equal Weight Health...
FHLC Fidelity® MSCI Health Care Index ETF

Holdings

Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
BIVV Bioverativ Inc5.08%
JUNO Juno Therapeutics Inc3.99%
FGEN FibroGen Inc3.86%
NKTR Nektar Therapeutics3.68%
AGIO Agios Pharmaceuticals Inc3.55%
ACAD ACADIA Pharmaceuticals Inc3.50%
RARE Ultragenyx Pharmaceutical Inc3.42%
ICPT Intercept Pharmaceuticals Inc3.39%
VRTX Vertex Pharmaceuticals Inc3.34%
NBIX Neurocrine Biosciences Inc3.34%